Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.56 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197077 | 0.89 | ELANE (0.50) | ESR1ESR2ELANEOPRK1PPARG | |
| SCHEMBL3414927 | 0.88 | ESR1 (0.56) | ESR1ESR2MEN1KMT2AKDM4E | |
| SCHEMBL57369 | 0.87 | MEN1 (0.57) | ESR1ESR2ELANEMEN1KMT2A | |
| SCHEMBL23280868 | 0.82 | LTA4H (0.61) | ELANELTA4H | |
| SCHEMBL3417993 | 0.81 | ESR2 (0.58) | ESR1ESR2MEN1KMT2AKDM4E | |
| SCHEMBL19491810 | 0.81 | ESR2 (0.58) | ESR1ESR2MEN1KMT2AKDM4E | |
| SCHEMBL3421064 | 0.81 | ESR2 (0.64) | ESR1ESR2ELANEMEN1KMT2A | |
| SCHEMBL24732178 | 0.80 | ELANE (0.83) | ELANEOPRK1PPARGPPARAACACB | |
| SCHEMBL16281923 | 0.80 | APP (0.47) | ELANEMEN1KMT2AOPRK1APP | |
| SCHEMBL7938063 | 0.80 | ESR1 (0.56) | ESR1ESR2ELANEPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767739-B2 | Cyanato group-containing cyclic phosphazene compound and method for producing the same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | CENPE, CPNE4, MCM3 | ESR1 3389/4885ESR2 3003/4885ELANE 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.